Ginkgo Bioworks Announces Date of First Quarter 2022 Results Presentation
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) will host a presentation and Q&A session on May 16, 2022, at 4:30 p.m. ET, to review its first-quarter performance ending March 31, 2022. The session will be accessible via Ginkgo's investor relations website, where a replay will also be available. This meeting aims to provide investors with insights into Ginkgo's business metrics and future projections, reinforcing its position in the biotechnology sector with applications in various markets including food, agriculture, and pharmaceuticals.
Positive
- Scheduled Q&A session provides transparent communication to shareholders.
- Business performance review indicates Ginkgo's commitment to investor relations.
Negative
- None.
News Market Reaction – DNA
In the trading session that priced this news, DNA declined 12.18%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presentation and Q&A session scheduled for post-market on Monday, May 16, 2022
BOSTON, May 9, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2022, on Monday, May 16, 2022, beginning at 4:30 p.m. ET.
The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.
To ask a question ahead of the presentation, please submit them to @Ginkgo on Twitter (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit https://www.ginkgobioworks.com/.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-date-of-first-quarter-2022-results-presentation-301542271.html
SOURCE Ginkgo Bioworks